281 related articles for article (PubMed ID: 28818671)
21. Anti-vascular endothelial growth factor antibody bevacizumab reduced the risk of anemia associated with chemotherapy-A meta-analysis.
Sher A; Wu S
Acta Oncol; 2011 Oct; 50(7):997-1005. PubMed ID: 21554028
[TBL] [Abstract][Full Text] [Related]
22. Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab.
Arnold D; Fuchs CS; Tabernero J; Ohtsu A; Zhu AX; Garon EB; Mackey JR; Paz-Ares L; Baron AD; Okusaka T; Yoshino T; Yoon HH; Das M; Ferry D; Zhang Y; Lin Y; Binder P; Sashegyi A; Chau I
Ann Oncol; 2017 Dec; 28(12):2932-2942. PubMed ID: 28950290
[TBL] [Abstract][Full Text] [Related]
23. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
24. Incidence and risk of hemorrhagic events with vascular endothelial growth factor receptor tyrosine-kinase inhibitors: an up-to-date meta-analysis of 27 randomized controlled trials.
Qi WX; Tang LN; Sun YJ; He AN; Lin F; Shen Z; Yao Y
Ann Oncol; 2013 Dec; 24(12):2943-52. PubMed ID: 23921791
[TBL] [Abstract][Full Text] [Related]
25. Predicting and preventing cardiotoxicity in the era of breast cancer targeted therapies. Novel molecular tools for clinical issues.
Zambelli A; Della Porta MG; Eleuteri E; De Giuli L; Catalano O; Tondini C; Riccardi A
Breast; 2011 Apr; 20(2):176-83. PubMed ID: 21146409
[TBL] [Abstract][Full Text] [Related]
26. Increased risk of high-grade hypertension with bevacizumab in cancer patients: a meta-analysis.
Ranpura V; Pulipati B; Chu D; Zhu X; Wu S
Am J Hypertens; 2010 May; 23(5):460-8. PubMed ID: 20186127
[TBL] [Abstract][Full Text] [Related]
27. Meta-analysis of randomized controlled trials for the incidence and risk of treatment-related mortality in patients with breast cancer treated with HER2 blockade.
Wu J; Qiu K; Zhu J; Li J; Lin Y; He Z; Li G
Breast; 2015 Dec; 24(6):699-704. PubMed ID: 26376461
[TBL] [Abstract][Full Text] [Related]
28. Incidence and risk of xerosis with targeted anticancer therapies.
Valentine J; Belum VR; Duran J; Ciccolini K; Schindler K; Wu S; Lacouture ME
J Am Acad Dermatol; 2015 Apr; 72(4):656-67. PubMed ID: 25637330
[TBL] [Abstract][Full Text] [Related]
29. Risk of venous and arterial thromboembolic events associated with anti-EGFR agents: a meta-analysis of randomized clinical trials.
Petrelli F; Cabiddu M; Borgonovo K; Barni S
Ann Oncol; 2012 Jul; 23(7):1672-9. PubMed ID: 22241897
[TBL] [Abstract][Full Text] [Related]
30. Targeted therapy for metastatic colorectal cancer: role of aflibercept.
Mitchell EP
Clin Colorectal Cancer; 2013 Jun; 12(2):73-85. PubMed ID: 23102896
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and adverse events of aflibercept, ranibizumab and bevacizumab in age-related macular degeneration: a trade-off analysis.
Schmid MK; Bachmann LM; Fäs L; Kessels AG; Job OM; Thiel MA
Br J Ophthalmol; 2015 Feb; 99(2):141-6. PubMed ID: 25271911
[TBL] [Abstract][Full Text] [Related]
32. Treatment-related mortality with aflibercept in cancer patients: a meta-analysis.
Qi WX; Tang LN; Shen Z; Yao Y
Eur J Clin Pharmacol; 2014 Apr; 70(4):461-7. PubMed ID: 24390630
[TBL] [Abstract][Full Text] [Related]
33. Risk of cutaneous toxicities in patients with solid tumors treated with immune checkpoint inhibitors: a meta-analysis.
Abdel-Rahman O; ElHalawani H; Fouad M
Future Oncol; 2015; 11(17):2471-84. PubMed ID: 26274495
[TBL] [Abstract][Full Text] [Related]
34. The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies.
Ciccarese C; Iacovelli R; Bria E; Modena A; Massari F; Brunelli M; Fantinel E; Bimbatti D; Zamboni GA; Artibani W; Tortora G
Immunotherapy; 2017 Jun; 9(7):579-587. PubMed ID: 28595514
[TBL] [Abstract][Full Text] [Related]
35. Incidence and risk of hypertension with pazopanib in patients with cancer: a meta-analysis.
Qi WX; Lin F; Sun YJ; Tang LN; He AN; Yao Y; Shen Z
Cancer Chemother Pharmacol; 2013 Feb; 71(2):431-9. PubMed ID: 23178953
[TBL] [Abstract][Full Text] [Related]
36. Risk of hand-foot skin reaction associated with vascular endothelial growth factor-tyrosine kinase inhibitors: A meta-analysis of 57 randomized controlled trials involving 24,956 patients.
Ding F; Liu B; Wang Y
J Am Acad Dermatol; 2020 Sep; 83(3):788-796. PubMed ID: 30991119
[TBL] [Abstract][Full Text] [Related]
37. Incidence and risk of proteinuria associated with newly approved vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: an up-to-date meta-analysis of randomized controlled trials.
Zhang W; Feng LJ; Teng F; Li YH; Zhang X; Ran YG
Expert Rev Clin Pharmacol; 2020 Mar; 13(3):311-320. PubMed ID: 32105149
[No Abstract] [Full Text] [Related]
38. Risk of gastrointestinal perforation in cancer patients receiving ramucirumab: a meta-analysis of randomized controlled trials.
Wang Z; Zhang J; Zhang L; Liu P; Xie Y; Zhou Q
J Chemother; 2016 Aug; 28(4):328-34. PubMed ID: 26099278
[TBL] [Abstract][Full Text] [Related]
39. Toxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trials.
Costa R; Carneiro BA; Agulnik M; Rademaker AW; Pai SG; Villaflor VM; Cristofanilli M; Sosman JA; Giles FJ
Oncotarget; 2017 Jan; 8(5):8910-8920. PubMed ID: 27852042
[TBL] [Abstract][Full Text] [Related]
40. Incidence and risk of treatment-related mortality with anti-epidermal growth factor receptor monoclonal antibody in cancer patients: a meta-analysis of 21 randomized controlled trials.
Li X; Shan BE; Wang J; Xing LP; Guo XJ; Zhang YH; Shi PH; Wang ZY
PLoS One; 2013; 8(11):e81897. PubMed ID: 24312376
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
